Differential conditioned fear response predicts duloxetine treatment outcome in male veterans with PTSD: A pilot study

Psychiatry Research

Volumn 188, Issue 3, 2011, Pages 453-455

  Aikins, Deane E ^a,b   Jackson, Eric D ^b   Christensen, Alicia ^b   Walderhaug, Espen ^a,b   Afroz, Sonia ^c   Neumeister, Alexander ^b,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b National Center for Posttraumatic Stress Disorder   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Conditioning; Duloxetine; PTSD

Indexed keywords

BIOLOGICAL MARKER; DULOXETINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONDITIONING; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEAR; HUMAN; MALE; PILOT STUDY; POSTTRAUMATIC STRESS DISORDER; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; VETERAN;

ANTIDEPRESSIVE AGENTS; CONDITIONING (PSYCHOLOGY); FEAR; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PILOT PROJECTS; STRESS DISORDERS, POST-TRAUMATIC; THIOPHENES; VETERANS;

EID: 79960698145     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.05.009     Document Type: Article

References (18)

1. Aikins D.E., Douglas C.J., Borelli J.L., Klemanski D., Morrissey P.M., Benham T.L., Southwick S.M., Tolin D.F. Thought suppression failures in combat PTSD: A cognitive load hypothesis. Behavior Research and Therapy 2009, 47:744-751.
2. Blechert J., Michael T., Vriends N., Margraf W. Fear conditioning in posttraumatic stress disorder: evidence for delayed extinction of autonomic, experiential, and behavioural responses. Behaviour Research and Therapy 2007, 45:2019-2033.
3. Bleich A., Koslowsky M., Dolev A., Lerer B. Post-traumatic stress disorder and depression: an analysis of comorbidity. British Journal of Psychiatry 1997, 170:479-482.
4. Bond A.J., Wingrove J., Baylis M., Dalton J. Buspirone decreases physiological reactivity to unconditioned and conditioned aversive stimuli. Psychopharmacology 2003, 165:291-295.
5. Bremner J.D., Vermetten E., Schmahl C., Vaccarino V., Vythilingam M., Afzal N., Grillon C., Charney D.S. Positron emission tomographic imaging of neural correlates of a fear acquisition and extinction paradigm in women with childhood sexual-abuse-related post-traumatic stress disorder. Psychological Medicine 2005, 35:791-806.
6. Davis M.F., Tsui J., Flannery J.A., Li X., DeLorey T.M., Hoffman B.B. Activation of alpha 2 adrenergic receptors suppresses fear conditioning: expression of c-Fos and phosphorylated CREB in mouse amygdala. Neuropsychopharmacology 2004, 29:229-239.
7. Green B.L., Krupnick J.L., Chung J., Siddique J., Krause E.D., Revicki D., Frank L., Miranda J. Impact of PTSD comorbidity on one-year outcomes in a depression trial. Journal of Clinical Psychology 2006, 62:815-835.
8. Guimaraes F.S., Hellewell J., Hensman R., Wang M., Deakin J.F.W. Characterization of a psychophysiological model of classical fear conditioning in healthy volunteers: influence of gender, instruction, personality, and placebo. Psychopharmacology 1991, 104:1432-2072.
9. Hamann S., Monarch E.S., Goldstein F.C. Impaired fear conditioning in Alzheimer's disease. Neuropsychologia 2002, 40:1187-1195.
10. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959, 32:50-55.
11. Krystal J.H., Neumeister A. Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. Brain Research 2009, 1293:13-23.
12. LeDoux J. Cognitive-emotional interactions: listen to the brain 2000, Oxford University Press, New York City, New York.
13. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979, 134:382-389.
14. Oler J.A., Markus E.J. Age-related deficits in on the radial maze and in fear conditioning: hippocampal processing and consolidation. Hippocampus 1998, 8:402-415.
15. Orr S.P., Metzger L.J., Lasko N.B., Macklin M.L., Peri T., Pitman R.K. De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. Journal of Abnormal Psychology 2000, 109:290-298.
16. Ravindran L.N., Stein M.B. Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Research 2009, 1293:24-39.
17. Walderhaug E., Kasserman S., Aikins D.E., Vojvoda D., Nishimura C., Neumeister A. Effects of duloxetine in treatment-refractory men with posttraumatic stress disorder. Pharmacopsychiatry 2010, 43:45-49.
18. Weathers F., Litz B., Herman D., Juska J., Keane T.M. The PTSD Checklist (PCL): Reliability, validity, and diagnostic. Presented at the Annual Meeting of the International Society for Traumatic Stress Studies, San Antonio, TX 1993.